Fulton Bank N.A. Has $3.39 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Fulton Bank N.A. decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 10.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 55,502 shares of the biopharmaceutical company's stock after selling 6,747 shares during the quarter. Fulton Bank N.A.'s holdings in Bristol-Myers Squibb were worth $3,385,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in BMY. Pinney & Scofield Inc. acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $25,000. Park Square Financial Group LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $26,000. Global Wealth Strategies & Associates boosted its holdings in Bristol-Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 275 shares during the last quarter. Transce3nd LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Finally, Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insiders Place Their Bets

In other news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Down 0.2%

NYSE BMY traded down $0.08 during trading on Wednesday, reaching $48.01. 11,194,047 shares of the stock traded hands, compared to its average volume of 13,058,998. The firm has a market cap of $97.70 billion, a price-to-earnings ratio of -10.86, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The stock's 50-day moving average price is $50.06 and its 200 day moving average price is $55.24. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($4.40) earnings per share. Analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Piper Sandler assumed coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. Jefferies Financial Group reduced their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.